Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following the approval, Pluvicto has become the first targeted radioligand therapy to be commercially available to prevent advanced prostate cancer in individuals. Pluvicto in combination with androgen deprivation therapy (ADT) with […]